X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the license agreement, Nektar will utilize the Biolojic Design program TNFR2 receptor agonist, currently undergoing early-stage clinical trials for treating autoimmune diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undiclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nektar Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 24, 2024
Details:
Under the agreement, Teva will receive exclusive rights to develop, manufacture and commercialize a potential novel antibody-based therapy, BD9, a dual specific antibody that can block both TSLP and IL-13, for the treatment of Atopic Dermatitis and Asthma.
Lead Product(s): BD9
Therapeutic Area: Dermatology Product Name: BD9
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2023
Details:
AU-007 is a human monoclonal antibody computationally designed by Biolojic Design, with a highly differentiated approach to harnessing the power of interleukin-2 (IL-2) to eradicate solid tumors.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Aulos
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
The trial will evaluate AU-007, a highly differentiated monoclonal antibody that was computationally designed by Biolojic and harnesses the power of the body's own interleukin-2 (IL-2) to eradicate solid cancer tumors.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Aulos
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
The research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.
Lead Product(s): Antibody-based therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $121.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
